← Research library

Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes

Lab research · 2008

What was studied
Murine macrophages, thymocytes and isolated membranes
Main finding
Radiolabeled gamma-D-Glu-L-Trp bound mouse immune cells; unlabeled Thymogen competed for binding. This supports a shared binding interaction under assay conditions, not equivalent immunological outcomes in people.

Bestim binding Kd, intact macrophages/thymocytes · 2.1 ± 0.1 / 3.1 ± 0.2 nM

Reported findings and study design

Radiolabeled Bestim binding to mouse macrophages/thymocytes and isolated membranes; tracer activity 45 Ci/mmol.

Population or model Murine macrophages, thymocytes and isolated membranes

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Bestim binding Kd, intact macrophages/thymocytes2.1 ± 0.1 / 3.1 ± 0.2 nM
Bestim binding Kd, isolated membranes18.6 ± 0.2 / 16.7 ± 0.3 nM
Thymogen competition Ki0.9 ± 0.1 / 1.1 ± 0.1 nM
Bestim adenylate-cyclase inhibition range10⁻¹⁰–10⁻⁶ M

Binding affinities are not clinical dose equivalences. The Ki row concerns Thymogen competition, not Bestim Kd.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Cell-binding experiment, not a clinical trial.
  • Preserve gamma linkage and D/L stereochemistry; generic database synonyms may be misleading.

Source details

Selected original-source text checked; full methodological review pending.

Selected text reviewed

Sources checked

Citation

In vitroEnglish abstract

Author unconfirmed. Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes Primary source linked above

Study source ↗ · DOI 10.1134/S1068162008010044 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards